Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Oct;43(10):2435-41.
doi: 10.1007/s10803-013-1793-z.

Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders

Brian Reichow  1 , Fred R Volkmar, Michael H Bloch
Affiliations
Meta-Analysis

Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders

Brian Reichow et al. J Autism Dev Disord. 2013 Oct.

Abstract

Many children with pervasive developmental disorders (PDD) exhibit behaviors and symptoms of attention-deficit/hyperactivity disorder (ADHD). We sought to determine the relative efficacy of medications for treating ADHD symptoms in children with PDD by identifying all double-blind, randomized, placebo-controlled trials examining the efficacy of medications for treating ADHD symptoms in children with PDD. We located seven trials involving 225 children. A random effects meta-analysis of four methylphenidate trials showed methylphenidate to be effective for treating ADHD symptoms in children with PDD (ES = .67). Several adverse events were greater for children were taking methylphenidate compared to placebo. An individual trial of clonidine and two trials of atomoxetine suggest these agents may also be effective in treating ADHD symptoms in children with PDD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study inclusion decision tree (using PRISMA flow diagram, of Moher et al., 2009)
Figure 2
Figure 2
Forrest Plot of Effect Size Estimates for Differences in ADHD Symptomatology
See this image and copyright information in PMC

References

    1. Aman MG, Arnold L, McDougle CJ, Vitiello B, Scahill L, Davies M, et al. Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology. 2005;15(6):869–884. - PubMed
    1. Arnold LE, Aman MG, Cook AM, Witwer AN, Hall KL, Thompson S, Ramadan Y. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. Journal of the American Academy of Child & Adolescent Psychiatry. 2006;45(10):1196–1205. - PubMed
    1. American Psychiatric Association . Diagnostic and Statistical Manual. 4th ed., text revision Author; Washington, D.C.: 2000.
    1. Borenstein M,HL, Higgins J, Rothstein H. Comprehensive Meta-Analysis 2. Biostat; Englewood, NJ: 2005.
    1. Cheng JYW, Chen RYL, Ko JSN, Ng EML. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents - meta-analytsis and meta-regression analysis. Pyschopharmacology. 2007;194(2):197–209. - PubMed

Publication types

MeSH terms

LinkOut - more resources